Inventor · disambiguated record
Xiping Cheng
Also filed as: CHENG XIPING
11 granted patents·6 pending applications·29 citations·filing 2018–2025
87Inventor score
Files withREGENERON PHARMA17
Top patents by PatentIndex Score
17 records- 0195US11180757B117β-hydroxysteroid dehydrogenase type 13 (HSD17B13) iRNA compositions and methods of use thereofREGENERON PHARMA·Filed 2021·Granted Nov 23, 2021·3 cites·30 claims
- 0294US11702700B2Inhibition of HSD17B13 in the treatment of liver disease in patients expressing the PNPLA3 I148M variationREGENERON PHARMA·Filed 2021·Granted Jul 18, 2023·4 cites·27 claims
- 0394US10787647B2HSD17B13 variants and uses thereofREGENERON PHARMA·Filed 2018·Granted Sep 29, 2020·10 cites·52 claims
- 0492US11753628B2HSD17B13 variants and uses thereofREGENERON PHARMA·Filed 2022·Granted Sep 12, 2023·1 cites·26 claims
- 0592US10961583B2Inhibition of HSD17B13 in the treatment of liver disease in patients expressing the PNPLA3 I148M variationREGENERON PHARMA·Filed 2018·Granted Mar 30, 2021·9 cites·29 claims
- 0686US2024141305A1Hsd17b13 variants and uses thereofREGENERON PHARMA·Filed 2023·Application pending·0 cites
- 0784US12286677B2Inhibition of HSD17B13 in the treatment of liver disease in patients expressing the PNPLA3 I148M variationREGENERON PHARMA·Filed 2023·Granted Apr 29, 2025·0 cites·14 claims
- 0884US11845963B2HSD17B13 variants and uses thereofREGENERON PHARMA·Filed 2018·Granted Dec 19, 2023·1 cites·12 claims
- 0984US11485958B2HSD17B13 variants and uses thereofREGENERON PHARMA·Filed 2020·Granted Nov 1, 2022·1 cites·40 claims
- 1080US2023031669A1Hsd17b13 variants and uses thereofREGENERON PHARMA·Filed 2022·Application pending·0 cites
- 1177US2025101119A1Methods of treating urea cycle disorders by interfering with glucagon receptor signalingREGENERON PHARMA·Filed 2024·Application pending·0 cites
- 1276US2025333737A117ß-HYDROXYSTEROID DEHYDROGENASE TYPE 13 (HSD17B13) iRNA COMPOSITIONS AND METHODS OF USE THEREOFREGENERON PHARMA·Filed 2025·Application pending·0 cites
- 1374US2025305050A1Inhibition Of HSD17B13 In The Treatment Of Liver Disease In Patients Expressing The PNPLA3 I148M VariationREGENERON PHARMA·Filed 2025·Application pending·0 cites
- 1470US12359201B217ß-hydroxysteroid dehydrogenase type 13 (HSD17B13) iRNA compositions and methods of use thereofREGENERON PHARMA·Filed 2019·Granted Jul 15, 2025·0 cites·39 claims
- 1565US12139546B2Methods of treating urea cycle disorders by interfering with glucagon receptor signalingREGENERON PHARMA·Filed 2018·Granted Nov 12, 2024·0 cites·18 claims
- 1659US12250931B2Genetically modified mouse with a humanized PNPLA3 gene and methods of useREGENERON PHARMA·Filed 2021·Granted Mar 18, 2025·0 cites·23 claims
- 1754US2023193392A1Methods Of Identifying And Evaluating Liver Inflammation And Liver Fibrosis In A Subject By Determining A Stratified Score Based On Gene ExpressionREGENERON PHARMA·Filed 2022·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Xiping Cheng files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →